SWM
BTAI icon

Spire Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

Spire Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8
Closed -$872 – 2371
2023
Q2 		$872 Hold
8
– – ﹤0.01% 2325
2023
Q1 		$2.44K Hold
8
– – ﹤0.01% 2221
2022
Q4 		$3K Hold
8
– – ﹤0.01% 1946
2022
Q3 		$2K Hold
8
– – ﹤0.01% 1927
2022
Q2 		$2K Hold
8
– – ﹤0.01% 2332
2022
Q1 		$3K Hold
8
– – ﹤0.01% 2317
2021
Q4 		$3K Hold
8
– – ﹤0.01% 2680
2021
Q3 		$4K Hold
8
– – ﹤0.01% 2319
2021
Q2 		$4K Buy
+8
New +$4.36K ﹤0.01% 2346

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spire Wealth Management's BTAI Position: Q3 2023 in Review

Spire Wealth Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 8 shares — an estimated $872 sold.

Spire Wealth Management first reported a position in BTAI in Q2 2021 and held it in 9 quarters. The position peaked at $4K in Q3 2021. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Spire Wealth Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Spire Wealth Management sold 8 BioXcel Therapeutics shares in Q3 2023, an estimated $872.
  • Spire Wealth Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 9 quarters.
  • Spire Wealth Management's BioXcel Therapeutics position peaked at $4K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Spire Wealth Management's 13F filing for Q3 2023, filed 8 Nov 2023.